Seltrion has recruited more than 70% of all clinical second-phase test takers for the development of Corona 19 antibody treatment

Seltrion has recruited more than 70% of all 수원룸싸롱 clinical second-phase test takers for the development of Corona 19 antibody treatment, approaching the planned application for emergency use approval. It was found that more than 200 people were recruited in November alone, breaking concerns that they would have difficulty recruiting Corona 19 patients, 분당룸싸롱 securing the first test subjects only in October after the approval of the clinical second phase plan in September. While widening the gap with European companies, it seems to be closely chasing Eli Lilly and Regeneron, who received emergency approval from the U.S. Food and Drug Administration (FDA). It is observed that Celtrion could 신림룸싸롱 become the world's third-most approved antibody treatment developer.